Gilead Sciences (NASDAQ:GILD) Downgraded by BidaskClub

Share on StockTwits

BidaskClub lowered shares of Gilead Sciences (NASDAQ:GILD) from a hold rating to a sell rating in a research report released on Wednesday morning, BidAskClub reports.

A number of other equities research analysts also recently weighed in on GILD. Jefferies Financial Group reissued a buy rating and set a $89.00 target price on shares of Gilead Sciences in a report on Monday, April 13th. Wolfe Research started coverage on Gilead Sciences in a report on Tuesday, March 31st. They set a market perform rating and a $65.00 target price for the company. Piper Sandler reissued a buy rating and set a $90.00 target price on shares of Gilead Sciences in a report on Thursday, April 16th. ValuEngine downgraded Gilead Sciences from a hold rating to a sell rating in a report on Friday, May 1st. Finally, Raymond James downgraded Gilead Sciences from an outperform rating to a market perform rating in a research note on Friday, May 1st. Seven equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $78.15.

Shares of GILD traded down $0.16 during midday trading on Wednesday, reaching $73.34. 6,157,451 shares of the stock were exchanged, compared to its average volume of 19,139,120. Gilead Sciences has a twelve month low of $60.89 and a twelve month high of $85.97. The company has a quick ratio of 2.92, a current ratio of 3.04 and a debt-to-equity ratio of 1.00. The company has a market cap of $92.20 billion, a P/E ratio of 18.85, a PEG ratio of 3.14 and a beta of 0.72. The stock’s 50 day simple moving average is $77.78 and its 200 day simple moving average is $70.16.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.57 by $0.11. Gilead Sciences had a return on equity of 35.44% and a net margin of 21.84%. The company had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter last year, the firm earned $1.67 earnings per share. The company’s revenue was up 5.1% on a year-over-year basis. As a group, analysts predict that Gilead Sciences will post 6.34 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Friday, June 12th will be paid a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.71%. The ex-dividend date of this dividend is Thursday, June 11th. Gilead Sciences’s payout ratio is 44.30%.

In other news, Director John Francis Cogan sold 2,413 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $77.97, for a total transaction of $188,141.61. Following the sale, the director now directly owns 57,273 shares in the company, valued at $4,465,575.81. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Brett A. Pletcher sold 2,950 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $75.55, for a total value of $222,872.50. Following the sale, the executive vice president now owns 17,594 shares in the company, valued at $1,329,226.70. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 60,585 shares of company stock worth $4,671,283. Company insiders own 0.13% of the company’s stock.

Several large investors have recently added to or reduced their stakes in GILD. Buckingham Asset Management LLC boosted its holdings in shares of Gilead Sciences by 2.3% during the 1st quarter. Buckingham Asset Management LLC now owns 5,911 shares of the biopharmaceutical company’s stock worth $442,000 after buying an additional 131 shares in the last quarter. Baldwin Brothers Inc. MA raised its position in shares of Gilead Sciences by 63.3% during the first quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 136 shares during the period. Twin Focus Capital Partners LLC raised its position in Gilead Sciences by 2.1% in the 1st quarter. Twin Focus Capital Partners LLC now owns 6,537 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 137 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its position in Gilead Sciences by 4.2% in the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 3,605 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 144 shares during the last quarter. Finally, Institute for Wealth Management LLC. raised its position in Gilead Sciences by 1.3% in the 4th quarter. Institute for Wealth Management LLC. now owns 11,104 shares of the biopharmaceutical company’s stock valued at $722,000 after buying an additional 145 shares during the last quarter. Institutional investors own 77.34% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: What is Elliott Wave theory?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.